Deka Bank Deutsche Girozentrale Tricida, Inc. Transaction History

Deka Bank Deutsche Girozentrale

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$8.51 - $13.6 $170,200 - $272,000	20,000 New	20,000 $197,000
Q4 2021 Feb 02, 2022	SELL	$4.19 - $9.56 $69,135 - $157,740	-16,500 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$8.56 - $26.93 $141,240 - $444,345	16,500 New	16,500 $137,000
Q1 2019 May 10, 2019	SELL	$19.96 - $38.62 $339,320 - $656,540	-17,000 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$23.57 - $32.33 $400,690 - $549,610	17,000 New	17,000 $402,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.